Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Buy” from Analysts

by · The Markets Daily

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $6.63.

A number of research firms have weighed in on TSHA. Canaccord Genuity Group upped their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Finally, JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th.

Read Our Latest Stock Analysis on Taysha Gene Therapies

Taysha Gene Therapies Trading Down 1.1 %

NASDAQ TSHA opened at $1.73 on Thursday. The company’s fifty day simple moving average is $2.12 and its 200-day simple moving average is $2.23. The stock has a market cap of $354.55 million, a P/E ratio of 2.75 and a beta of 0.79. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning acquired a new position in shares of Taysha Gene Therapies during the third quarter worth approximately $28,000. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies in the second quarter worth $48,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Taysha Gene Therapies by 79.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after purchasing an additional 17,446 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Taysha Gene Therapies during the third quarter valued at $85,000. Finally, Scientech Research LLC bought a new stake in shares of Taysha Gene Therapies during the second quarter valued at about $97,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

(Get Free Report

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Articles